Minimal change nephrotic syndrome in a patient with strongyloidiasis

Clinical and Experimental Nephrology

Volumn 14, Issue 4, 2010, Pages 367-371

  Miyazaki, Mieko ^a   Tamura, Masahito ^a   Kabashima, Narutoshi ^a   Serino, Ryota ^a   Shibata, Tatsuya ^a   Miyamoto, Tetsu ^a   Furuno, Yumi ^a   Nishio, Tetsuo ^b   Ohara, Jiro ^b   Sakurai, Toshihiro ^b   Otsuji, Yutaka ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

Immunosuppression; Minimal change nephrotic syndrome; Opportunistic infectious disease; Steroid; Strongyloidiasis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; IMMUNOGLOBULIN E; IVERMECTIN; PREDNISOLONE; STEROID;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL MENINGITIS; CASE REPORT; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; EOSINOPHILIA; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPOALBUMINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; LEG EDEMA; MALE; MALNUTRITION; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; PNEUMONIA; PROTEINURIA; STEROID THERAPY; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; VOMITING; WEIGHT REDUCTION;

AGED; ANIMALS; ANTIPARASITIC AGENTS; BIOPSY; DIARRHEA; EDEMA; FATAL OUTCOME; GLUCOCORTICOIDS; HUMANS; IVERMECTIN; KIDNEY; MALE; NEPHROSIS, LIPOID; PREDNISOLONE; PROTEINURIA; SEPSIS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TREATMENT OUTCOME;

EID: 78649490382     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0273-4     Document Type: Article

References (23)

1. Fardet L, Genereau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: Case series and literature review. J Infect. 2007;54:18-27.
2. Saito A. Strongyloidiasis-progress in its diagnosis and treatment. Nippon Naika Gakkai Zasshi. 2003;92:399-403.
3. Hsieh YP, Wen YK, Chen ML. Minimal change nephrotic syndrome in association with strongyloidiasis. Clin Nephrol. 2006;66:459-63.
4. Morimoto J, Kaneoka H, Sasatomi Y, Sato YN, Murata T, Ogahara S, et al. Disseminated strongyloidiasis in nephrotic syndrome. Clin Nephrol. 2002;57:398-401.
5. Sathe PA, Madiwale CV. Strongyloidiasis hyperinfection in a patient with membranoproliferative glomerulonephritis. J Postgrad Med. 2006;52:221-2.
6. Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: A retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis. 2006;25:14-8.
7. Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol. 2005;12:680-2.
8. Mitsunaga M, Miyauchi N, Akiyama Y, Saima S. A case of strongyloidiasis hyperinfection during oral corticosteroid therapy associated with a nephrotic patient infected with HTLV-1. Nippon Ronen Igakkai Zasshi. 2003;40:397-401.
9. Yee YK, Lam CS, Yung CY, Que TL, Kwan TH, Au TC, et al. Strongyloidiasis as a possible cause of nephrotic syndrome. Am J Kidney Dis. 1999;33:E4.
10. Wong TY, Szeto CC, Lai FF, Mak CK, Li PK. Nephrotic syndrome in strongyloidiasis: Remission after eradication with anthelmintic agents. Nephron. 1998;79:333-6.
11. Mori S, Konishi T, Matsuoka K, Deguchi M, Ohta M, Mizuno O, et al. Strongyloidiasis associated with nephrotic syndrome. Intern Med. 1998;37:606-10.
12. Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med. 1966;275:1093-6.
13. Willis AJ, Nwokolo C. Steroid therapy and strongyloidiasis. Lancet. 1966;1:1396-8.
14. Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy. 2006;4:8.
15. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992-2001.
16. Boonpucknavig V, Soontornniyomkij V. Pathology of renal diseases in the tropics. Semin Nephrol. 2003;23:88-106.
17. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150:2379-84.
18. Thomson PD. Renal problems in black South African children. Pediatr Nephrol. 1997;11:508-12.
19. Copelovitch L, Sam Ol O, Taraquinio S, Chanpheaktra N. Childhood nephrotic syndrome in Cambodia: An association with gastrointestinal parasites. J Pediatr. 2010;156:76-81.
20. Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991;44:243-5.
21. Bheekha-Escura R, MacGlashan DW, Langdon JM, MacDonald SM. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-3D10. Blood. 2000;96:2191-8.
22. Toyabe S, Kaneko U, Hara M, Uchiyama M. Expression of immunoglobulin E-dependent histamine-releasing factor in idiopathic nephrotic syndrome of childhood. Clin Exp Immunol. 2005;142:162-6.
23. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez- Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. 2004;5:2615-9.